Mangalam Drugs And Organics liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

0.82×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.79×	0.79×	1.04×	1.07×	—
0.27×	0.27×	0.31×	0.32×	—
0.7	0.7	2.6	0.9	2.7
−40.9	−40.9	7.4	11.9	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MANGALAM₹28.95

Mangalam Drugs And Organics Limited

· Pharma & Health

₹ CrorePeersBIOFILCHEM LASA VINEETLAB ORTINGLOBE KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹45.8 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	0.82
Current Ratio	—	1.07	1.04	0.79	0.79
Quick Ratio	—	0.32	0.31	0.27	0.27
Cash, Equiv & ST Investments	2.7	0.9	2.6	0.7	0.7
Working Capital	—	11.9	7.4	-40.9	-40.9

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.